NICE has assessed 5 tests (the IOTA ADNEX model, Overa [MIA2G], RMI I [at thresholds other than 250], ROMA and IOTA Simple Rules) to help the NHS decide whether to use them to identify people at high risk of ovarian cancer.
The tests are used by hospital specialists to help them decide whether to refer people with suspected ovarian cancer to a specialist multidisciplinary team for treatment.
NICE said that the RMI I can be used at a threshold of 200, as well as the threshold of 250 recommended in NICE’s guideline on ovarian cancer. The other tests and other thresholds for the RMI I show promise but more research is needed before they are used in the NHS.
This page was last updated: 15 November 2017